SML0877

Gardiquimod

≥98% (HPLC)

• Synonym(s): 1-(4-Amino-2-ethylaminomethylimidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol, 4-Amino-2-[(ethylamino)methyl]-?,?-dimethyl-1H-Imidazo[4,5-c]quinoline-1-ethanol
• Empirical Formula (Hill Notation): C₁₇H₂₃N₅O
• CAS Number: 1020412-43-4
• Molecular Weight: 313.40
• NACRES: NA.77

Properties

• Nível de qualidade: 100
• teor: ≥98% (HPLC)
• forma: powder
• cor: white to beige
• solubilidade: DMSO: 10 mg/mL, clear
• temperatura de armazenamento: −20°C

Description

Embalagem

5, 25 mg in glass bottle

Ações bioquímicas/fisiológicas

Gardiquimod is a potent and specific agonist for human or mouse Toll-like receptor 7 (TLR7). Also, at high concentration gardiquimod activates TLR8. Similarly to imiquimod, gardiquimod could mimic the effects of viral nucleic acids on the immune system.

Gardiquimod is developed as a new imidazoquinoline compound. It stimulates NF-κB (nuclear factor-κB) activation in cells expressing human or murine toll like receptor 7 (TLR7). Gardiquimod is found to be ten times more efficient than imiquimod. It induces splenocyte activation and prevents murine B16 melanoma growth and metastasis. Gardiquimod might serve as a therapeutic agent to prevent HIV-1 (human immunodeficiency virus - 1) transmission. It hinders the life cycle of HIV-1, by blocking the action of HIV-1 reverse transcriptase.

Características e benefícios

This compound is featured on the Cytokine Receptors (Interleukin-1 Receptor/TIR Family) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Safety Information

• Pictogramas: GHS07
• Palavra indicadora: Warning
• Frases de perigo: H315 - H319 - H335
• Declarações de precaução: P302 + P352 - P305 + P351 + P338
• Classificações de perigo: Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
• Órgãos-alvo: Respiratory system
• Código de classe de armazenamento: 11 - Combustible Solids
• WGK: WGK 3
• Ponto de fulgor (ºF): Not applicable
• Ponto de fulgor (ºC): Not applicable